Physician profile
Brandy R Biederman
NPI 1497041180
$447,637.75
in general payments reported to CMS, 2019-2025
42 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $66K · 2023: $138K · 2024: $113K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $262K · Travel and Lodging: $57K · Honoraria: $27K · Food and Beverage: $16K · Consulting Fee: $2,607 · Gift: $178 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262,234.63 |
| Travel and Lodging | $57,090.24 |
| Honoraria | $26,915.00 |
| Food and Beverage | $16,053.06 |
| Consulting Fee | $2,607.49 |
| Gift | $178.20 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $214,573.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $91,008.14 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Mannkind Corporation | $58,769.73 | 2022-2025 | Afrezza |
| Medtronic, INC. | $23,101.98 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $21,616.28 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $12,307.67 | 2022-2025 | |
| Intra-Sana Laboratories | $12,198.11 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Insulet Corporation | $10,291.49 | 2021-2025 | Omnipod |
| Antares Pharma, INC. | $503.18 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $451.62 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $338.82 | 2021-2025 | Unithroid |
| Sequel Med Tech, LLC | $225.19 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $173.07 | 2021-2024 | |
| Esperion Therapeutics, INC. | $169.49 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.66 | 2021-2025 | Jardiance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $154.00 | 2021 | |
| Cequr Corporation | $122.59 | 2022-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $120.39 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Biohaven Pharmaceuticals, INC. | $117.29 | 2021 | |
| Ascensia Diabetes Care US INC. | $108.02 | 2023 | |
| Pfizer INC. | $95.18 | 2021-2025 | |
| Corcept Therapeutics | $88.43 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $83.81 | 2021-2022 | |
| Abbott Laboratories | $77.00 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $72.67 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $72.29 | 2021-2025 | Otezla, Repatha, Repatha |
| Currax Pharmaceuticals LLC | $71.61 | 2022-2023 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $62.91 | 2021 | |
| Ibsa Pharma INC. | $59.15 | 2021-2025 | Tirosint, Flector, Licart |
| Tolmar, INC. | $53.90 | 2023 | |
| Novartis Pharmaceuticals Corporation | $51.85 | 2022-2025 | |
| Halozyme INC | $48.10 | 2023 | |
| Axsome Therapeutics, INC. | $42.92 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $36.99 | 2023 | Adthyza, Edarbyclor |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.70 | 2022 | |
| Scynexis, INC. | $36.40 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.56 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.35 | 2023 | Quviviq |
| Astellas Pharma US INC | $25.44 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.34 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $18.17 | 2021 | |
| Horizon Therapeutics Plc | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Biederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.